Innospera Pharma is a clinical‑stage biotechnology company developing lipid‑mimetic small molecules that restore dysregulated signaling pathways in fibrotic and chronic diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Idiopathic pulmonary fibrosis (IPF) involves reduced activity of peroxisome proliferator-activated receptors (PPARs) due to TGF‑β‑driven suppression and a depleted lipid environment, leading to unchecked fibrotic signaling. Existing therapies that directly inhibit fibrotic pathways often cause significant toxicities and have limited tolerability, leaving an unmet need for safer, mechanism‑based treatments.
Solution
Innospera Pharma is developing lipid‑mimetic small molecules that restore normal PPAR signaling in fibrotic disease. Its lead candidate, ING‑006, combines an allosteric modulator with an orthosteric agonist to reactivate PPAR activity specifically in diseased lung tissue while sparing healthy cells. This dual mechanism leverages robust Phase 2 data from a known pan‑PPAR agonist to de‑risk clinical development and supports a differentiated safety profile. ING‑006 is currently in Phase 1 trials for IPF, with early data indicating good tolerability in healthy volunteers. The company’s platform also includes next‑generation analogues (ING‑008 and others) designed for organ‑specific applications across fibrotic, metabolic, and oncology indications.
Target Audience
Primary customers are pharmaceutical companies and clinical development teams seeking novel, mechanism‑based therapies for IPF and other fibrotic, metabolic, or oncology indications.
Features
- Lipid‑mimetic small‑molecule scaffold that mimics endogenous fatty‑acid ligands to engage PPAR pathways
- Dual pharmacology: allosteric modulation plus orthosteric agonism for comprehensive PPAR activation
- Tissue‑selective activity that restores down‑regulated PPAR signaling without affecting normal PPAR‑active cells
- Safety de‑risking based on Phase 2 clinical data from a pan‑PPAR agonist and favorable toxicology in Phase 1
- Platform extensibility to generate analogues (e.g., ING‑008) with tailored potency, DMPK properties, and indication focus